

1. Patra JK, Das G, Fraceto LF *et al.* Nano based drug delivery systems: recent developments and future prospects. *J Nanobiotechnol.*(2018); 16: 71.
2. Martinho N, Damgé C, Reis CP. Recent advances in drug delivery systems. *J Biomater Nanobiotechnol.* 2011; 2:510.
3. Jahangirian H, Lemraski EG, Webster TJ, Rafiee-Moghaddam R, Abdollahi Y. A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine. *Int J Nanomed.* 2017; 12:2957.
4. Haba Y, Kojima C, Harada A, Ura T, Horinaka H, Kono K. Preparation of poly (ethylene glycol)-modified poly (amido amine) dendrimers encapsulating gold nanoparticles and their heat-generating ability. *Langmuir.* 2007; 23:5243–6.
5. De Villiers MM, Aramwit P, Kwon GS. *Nanotechnology in drug delivery.* New York: Springer; 2008.
6. Mirza AZ, Siddiqui FA. Nanomedicine and drug delivery: a mini review. *Int Nano Lett.* 2014; 4:94.
7. Kabanov AV, Lemieux P, Vinogradov S, Alakhov V. Pluronic block copolymers: novel functional molecules for gene therapy. *Adv Drug Deliv Rev.* 2002; 54:223–33.
8. Krauel K, Pitaksuteepong T, Davies NM, Rades T. Entrapment of bioactive molecules in poly (alkylcyanoacrylate) nanoparticles. *Am J Drug Deliv.* 2004; 2:251–9.
9. Mahajan HS, Patil SB, Gattani SG, Kuchekar BS. Targeted drug delivery systems. *Pharma Times.* 2007;39(2).
10. Rani K, Paliwal SA. Review on targeted drug delivery: its entire focus on advanced therapeutics and diagnostics. *Sch J App Med Sci.* 2014; 2(1C):328–331.

11. Bhardwaj A, Kumar L. Colloidal drug delivery systems: a future prospective for treatment of tuberculosis. *Am J PharmTech Res.* 2011; 1(3):102–123.
12. Arora S, Lamba HS, Tiwari R. Dermal delivery of drugs using different vesicular carriers. *Asian J Pharm.* 2012; 6:237. doi: 10.4103/0973-8398.107558.
13. Priya K, Kumar V, Damini VK, et al. Somes: a review on composition, formulation methods and evaluations of different types of “somes” drug delivery system. *Int J App Pharm.* 2020; 12(6):7–18.
14. Gattani YS. Floating Multiparticulate drug delivery systems: an overview. *Int J Pharma Bio Sci.* 2010;6(2):35–40.
15. Ravinder K, Sukhvir K. Role of polymers in drug delivery. *J Drug Deliv Ther.* 2014;4(3):32–36.
16. Haijiao L, Jingkang W, Ting W, Jian Z, Ying B, Hongxun H. Recent progress on nanostructures for drug delivery applications. *J Nanomater.* 2016; 2–9.
17. Yousaf A, Ali A, Sadiq A, Shafida A, Umar F. Macromolecules as targeted drugs delivery vehicles: an overview. *Des Monomers Polym.* 2019;22(1):91–97. doi: 10.1080/15685551.2019.1591681.
18. Rav S, Maina SS, Malviya R, Kushwah MG, Khan MG, Yezdani U. Novel approach of targeted drug delivery system and its application. *ARC J Public Health Commun Med.* 2019;4(4):1–4.
19. Kumar A, Nautiyal U, Kaur C, Goel V, Piarchand N. Targeted drug delivery system: current and novel approach. *Int J Pharm Med Res.* 2017; 5(2):448–454.
20. Wakaskar RR (2017) Types of Nanocarriers–Formulation Method and Applications. *J Bioequiv Availab* 9:e77.

21. Kumar A, Nautiyal U, Kaur C, Goel V, Piarchand N. Targeted drug delivery system: current and novel approach. *Int J Pharm Med Res.* 2017; 5(2):448–454.
22. Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. *Cancers.* 2019; 11:640. doi: 10.3390/cancers11050640.
23. Rani K, Paliwal SA. Review on targeted drug delivery: its entire focus on advanced therapeutics and diagnostics. *Sch J App Med Sci.* 2014; 2(1C):328–331.
24. Bhargav E, Madhuri N, Ramesh K, Manne A, Ravi V. Targeted drug delivery - a review. *World J Pharm Pharm Sci.* 2013;3(1):150–169.
25. Mills JK, Needham D. Targeted drug delivery. *Exp Opin Ther Patents.* 1999; 9(11):1499–1513. doi: 10.1517/13543776.9.11.1499.
26. Devarajan PV, Jain S, Editors. *Targeted Drug Delivery: Concepts and Design.* New York Dordrecht London: Springer Cham Heidelberg; 2015.
27. Manish G, Vimukta S. Targeted drug delivery system: a review. *Res J Chem Sci.* 2011; 1(2):135–138.
28. Thakur A, Roy A, Chatterjee S, Chakraborty P, Bhattacharya K, Mahata PP. Recent trends in targeted drug delivery. *SMGroup.* 2015.
29. Kivilcim O, Hakan E, Sema Ç. Novel advances in targeted drug delivery. *J Drug Target.* 2017. doi: 10.1080/1061186X.2017.1401076
30. Scott R, Crabbe D, Krynska B, Ansari R, Kiani M. Aiming for the heart: targeted delivery of drugs to diseased cardiac tissue. *Expert Opin Drug Deliv.* 2008; 5(4):459–470. doi: 10.1517/17425247.5.4.459

31. Idayu IM, Suguna S, Nurul A. Designing polymeric nanoparticles for targeted drug delivery system. *Nanomedicine*. 2015; 288–311.
32. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. *Nat Rev Clin Oncol*. 2018; 15(2):81–94. doi: 10.1038/nrclinonc.2017.166.
33. Viet CT, Schmidt BL. Understanding oral cancer in the genome era. *Head & neck*. 2010;32(9):1246–68.
34. R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics 2016, *CA Cancer J Clin*, 66 (2016), pp. 7-30.
35. Lodish H., Berk A., Zipursky S. L., Matsudaira P., Baltimore D., Darnell J. *Molecular Cell Biology*. 4th. New York, NY, USA: W. H. Freeman; 2000. Tumor cells and the onset of cancer.
36. Reymond N., D'Água B. B., Ridley A. J. Crossing the endothelial barrier during metastasis. *Nature Reviews Cancer*. 2013; 13(12):858–870. doi: 10.1038/nrc3628.
37. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. *Clinical Cancer Research*. 2003;9(2):551–554.
38. Nishida N., Yano H., Nishida T., Kamura T., Kojiro M. Angiogenesis in cancer. *Vascular Health and Risk Management*. 2006; 2(3):213–219. doi: 10.2147/vhrm.2006.2.3.213.
39. Murphy K, Travers P, Walport M. *Janeway's Immunobiology*. 7th. New York, NY, USA: Garland Science Taylor and Francis Group; 2008. Principles of innate and adaptive immunity; pp. 1–38.

40. Dinarello C. A. Historical review of cytokines. *European Journal of Immunology*. 2007; 37(supplement 1):S34–S45. doi: 10.1002/eji.200737772.
41. Wills-Karp M. Complement activation pathways: a bridge between innate and adaptive immune responses in asthma. *Proceedings of the American Thoracic Society*. 2007; 4(3):247–251. doi: 10.1513/pats.200704-046aw.
42. Sun JC, Lanier LL. Natural killer cells remember: an evolutionary bridge between innate and adaptive immunity? *European Journal of Immunology*. 2009; 39(8):2059–2064. doi: 10.1002/eji.200939435.
43. Murphy K., Travers P., Walport M. *Janeway's Immunobiology*. 7th. New York, NY, USA: Garland Science/Taylor and Francis Group; 2008. Structural variation in immunoglobulin constant regions; pp. 143–213.
44. Koretzky G. A. Multiple roles of CD4 and CD8 in T cell activation. *Journal of Immunology*. 2010; 185(5):2643–2644. doi: 10.4049/jimmunol.1090076.
45. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4 +T cells: differentiation and functions. *Clinical and Developmental Immunology*. 2012; 12. doi: 10.1155/2012/925135.925135.
46. Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. *Immunological Reviews*. 2009; 229(1):337–355. doi: 10.1111/j.1600-065X.2009.00773.x.
47. Janeway C. A., Jr., Travers P., Walport M., *Immunobiology: The Immune System in Health and Disease*. 5th. New York, NY, USA: Garland Science; 2001. B-cell activation by armed helper T cells.

48. Schroeder HW, Jr, Cavacini L. Structure and function of immunoglobulins. *Journal of Allergy and Clinical Immunology*. 2010; 125(2):S41–S52.
49. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. *Advances in Cancer Research*. 2008; 101:277–348. doi: 10.1016/s0065-230x(08)00408-9.
50. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA: A Cancer Journal for Clinicians* 2023; 73(1):17-48. Last accessed February 21, 2023.s
51. Jan AB. Treatment of Chronic Lymphocytic Leukemia. *The new England journal of medicine* 2020; 383:460-473, DOI: 10.1056/NEJMra1908213.
52. Bhutani M, Vora A, Kumar L, Kochupillai V. Lympho-hemopoietic malignancies in India. *Med Oncol*. 2002; 19(3):141-50. doi: 10.1385/MO:19:3:141. PMID: 12482124.
53. Yang J, Jia C, Yang J. Designing nanioparticle-based drug delivery system for precision medicine. *Int J Med Sci* 2021; 18(13):2943-2949. doi:10.7150/ijms.60874
54. Singh A, Garg G, Sharma PK. Nanosphere: A novel approach for targeted drug delivery. Volume 5, Issue 3, November – December 2010; Article-015. ISSN 0976 – 044X. b/,
55. Hwang D, Ramsey JD, Kabanov AV. Polymeric micelles for the delivery of poorly soluble drugs: From nano formulation to clinical approval. *Adv Drug Deliv Rev*. 2020; 156:80-118. doi: 10.1016/j.addr.2020.09.009. Epub 2020 Sep 24.
56. Maiti A, Bhattacharyya S. Review: Quantum Dots and Application in Medical Science. *International Journal of Chemistry and Chemical Engineering*. ISSN 2248-9924 Volume 3, Number 2 (2013), pp. 37-42.
57. Min KH , Park K, Kim Y, Bae SM, Lee S, *et al.* hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor

- targeting in cancer therapy, *Journal of Controlled Release, Volume 127, Issue 3, 8 May 2008, Pages 208-218.*
58. Park JH, Gurusamy S, Kim K, Targeted delivery of low molecular drugs using chitosan and its derivatives, *Advanced Drug Delivery Reviews, Volume 62, Issue 1, 31 January 2010, Pages 28-41.*
59. Wang J, Zong J, Zhao D. In situ formation of chitosan-cyclodextrin nanospheres for drug delivery. *Colloids and Surfaces B: Biointerfaces* 2011; 87: 198– 202.
60. Nanda R , Sasmal A, Nayak PL. Preparation and characterization of chitosan polylactide composites blended with Cloisite 30B for control release of the drug paclitaxel, Original Research Article *Carbohydrate Polymers, Volume 83, Issue 2, 10 January 2011, Pages 988-994.*
61. Nam J, Park S, Kim T, Jang J, Choi C, *et al.* formulated Encapsulation of paclitaxel into lauric acid-O-carboxymethyl chitosan-transferrin micelles for hydrophobic drug delivery and site-specific targeted delivery, *International Journal of Pharmaceutics, Volume 457, Issue 1, 30 November 2013, Pages 124-135.*
62. Feng C, Sun G, Wang Z, Cheng X, Park H, *et al.* Transport mechanism of doxorubicin loaded chitosan based nanogels across intestinal epithelium, *European Journal of Pharmaceutics and Biopharmaceutics, Volume 87, Issue 1, May 2014, Pages 197-207*
63. Lucio D , Zornoza A. Influence of chitosan and carboxymethyl chitosan on the polymorphism and solubilisation of diflunisal, *International Journal of Pharmaceutics, Volume 467, Issues 1–2, 5 June 2014, Pages 19-26.*
64. Khan I, Gothwal A, Sharma AK, Qayum A, Singh SK, Gupta U. Biodegradable nano-architectural PEGylated approach for the improved stability and anticancer efficacy of

- bendamustine. *Int J Biol Macromol.* 2016; 92:1242-1251.
doi:10.1016/j.ijbiomac.2016.08.004
65. Gidwani B, Vyas A. Formulation, characterization and evaluation of cyclodextrin-complexed bendamustine-encapsulated PLGA nanospheres for sustained delivery in cancer treatment. *Pharm Dev Technol.* 2016;21(2):161-171.
doi:10.3109/10837450.2014.979945
66. Franiak-Pietryga I, Ziółkowska E, Ziemba B, et al. Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays. *Anticancer Agents Med Chem.* 2017;17(1):102-114.
67. Bhandari J, Mishra H, Mishra PK, Wimmer R, Ahmad FJ, Talegaonkar S. Cellulose nanofiber aerogel as a promising biomaterial for customized oral drug delivery. *Int J Nanomedicine.* 2017;12:2021-2031. Published 2017 Mar 14. doi:10.2147/IJN.S124318
68. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. *Blood.* 2017 Jul 27;130(4):410-423. doi:10.1182/blood-2017-02-734541. Epub 2017 Jun 9.
69. Vinhas R, Mendes R, Fernandes AR, Baptista PV. Nanoparticles-Emerging Potential for Managing Leukemia and Lymphoma. *Front Bioeng Biotechnol.* 2017 Dec 18; 5:79. doi:10.3389/fbioe.2017.00079.
70. Hallek M, Shanafelt TD, Eichhorst B. Chronic lymphocytic leukaemia. *Lancet.* 2018;391(10129):1524-1537. doi:10.1016/S0140-6736(18)30422-7
71. Thomas SC, Madaan T, Iqbal Z, Talegaonkar S. Box-Behnken Design of Experiment Assisted Development and Optimization of Bendamustine HCl loaded Hydroxyapatite

- Nanoparticles. *Curr Drug Deliv.* 2018;15(9):1230-1244.
doi:10.2174/1567201815666180620123347
72. Ziembra B, Sikorska H, Jander M, et al. Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia. *Anticancer Agents Med Chem.* 2020;20(3):325-334.
doi:10.2174/1871520619666191019093558
73. Franiak-Pietryga I, Ziembra B, Sikorska H, et al. Maltotriose-modified poly(propylene imine) Glycodendrimers as a potential novel platform in the treatment of chronic lymphocytic Leukemia. A proof-of-concept pilot study in the animal model of CLL. *Toxicol Appl Pharmacol.* 2020; 403:115139. doi:10.1016/j.taap.2020.115139.
74. Shakeran Z, Keyhanfar M, Varshosaz J, Sutherland DS. Biodegradable nanocarriers based on chitosan-modified mesoporous silica nanoparticles for delivery of methotrexate for application in breast cancer treatment. *Mater Sci Eng C Mater Biol Appl.* 2021;118:111526. doi:10.1016/j.msec.2020.111526
75. Cavalcante RS, Ishikawa U, Silva ES, et al. STAT3/NF- κ B signalling disruption in M2 tumour-associated macrophages is a major target of PLGA nanocarriers/PD-L1 antibody immunomodulatory therapy in breast cancer. *Br J Pharmacol.* 2021;178(11):2284-2304.
doi:10.1111/bph.15373
76. Li L, Yang M, Li R, Hu J, Yu L, Qian X. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment. *Anticancer Agents Med Chem.* 2021;21(7):910-918.
doi:10.2174/1871520620666200721134919.

77. Ghilardi G, Chong EA, Svoboda J, et al. Bendamustine is safe and effective for lymphodepletion before tisagenlecleucel in patients with refractory or relapsed large B-cell lymphomas. *Ann Oncol.* 2022;33(9):916-928. doi:10.1016/j.annonc.2022.05.521
78. Ghaz-Jahanian MA, Abbaspour-Aghdam F, Anarjan N, Berenjian A, Jafarizadeh-Malmiri H. Application of chitosan-based nanocarriers in tumor-targeted drug delivery. *Mol Biotechnol.* 2015; 57(3):201-218. doi:10.1007/s12033-014-9816-3
79. Resen AK, Atiroğlu A, Atiroğlu V, et al. Effectiveness of 5-Fluorouracil and gemcitabine hydrochloride loaded iron-based chitosan-coated MIL-100 composite as an advanced, biocompatible, pH-sensitive and smart drug delivery system on breast cancer therapy. *Int J Biol Macromol.* 2022; 198:175-186. doi:10.1016/j.ijbiomac.2021.12.130
80. Priya S, Batra U, R N S, Sharma S, Chaurasiya A, Singhvi G. Polysaccharide-based nanofibers for pharmaceutical and biomedical applications: A review. *Int J Biol Macromol.* 2022; 218:209-224. doi:10.1016/j.ijbiomac.2022.07.118.
81. Rinaldi F, Forte J, Pontecorvi G, et al. pH-responsive oleic acid based nanocarriers: Melanoma treatment strategies. *Int J Pharm.* 2022; 613:121391. doi:10.1016/j.ijpharm.2021.121391.
82. Zhang N, Li J, Gao W, et al. Co-Delivery of Doxorubicin and Anti-PD-L1 Peptide in Lipid/PLGA Nanocomplexes for the Chemo-Immunotherapy of Cancer. *Mol Pharm.* 2022; 19(9):3439-3449. doi:10.1021/acs.molpharmaceut.2c00611
83. Xiong W, Guo Z, Zeng B, et al. Dacarbazine-Loaded Targeted Polymeric Nanoparticles for Enhancing Malignant Melanoma Therapy. *Front Bioeng Biotechnol.* 2022;10:847901. Published 2022 Feb 17. doi:10.3389/fbioe.2022.847901

84. Singh A, Thotakura N, Kumar R, et al. PLGA-soya lecithin based micelles for enhanced delivery of methotrexate: Cellular uptake, cytotoxic and pharmacokinetic evidences. *Int J Biol Macromol*. 2017; 95:750-756. doi:10.1016/j.ijbiomac.2016.11.111
85. Dennie TW, Kolesar JM. Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. *Clin Ther*. 2009; 31 Pt 2:2290-2311. doi:10.1016/j.clinthera.2009.11.031
86. Lalic H, Aurer I, Batinic D, Visnjic D, Smoljo T, Babic A. Bendamustine: A review of pharmacology, clinical use and immunological effects (Review). *Oncol Rep*. 2022; 47(6):114. doi:10.3892/or.2022.8325
87. Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. *Cancer Chemother Pharmacol*. 2015; 75(6):1143-1154. doi:10.1007/s00280-015-2727-6
88. Bogeljic Patekar M, Milunovic V, Misura Jakobac K, et al. Bendamustine: an old drug in the new era for patients with non-hodgkin lymphomas and chronic lymphocytic leukemia. *Acta Clin Croat*. 2018; 57(3):542-553. doi:10.20471/acc.2018.57.03.18
89. Elieh-Ali-Komi D, Hamblin MR. Chitin and Chitosan: Production and Application of Versatile Biomedical Nanomaterials. *Int J Adv Res (Indore)*. 2016; 4(3):411-427.
90. Cheung RC, Ng TB, Wong JH, Chan WY. Chitosan: An Update on Potential Biomedical and Pharmaceutical Applications. *Mar Drugs*. 2015; 13(8):5156-5186. Published 2015 Aug 14. doi:10.3390/md13085156
91. Yang W, Fu J, Wang T, He N. Chitosan/sodium tripolyphosphate nanoparticles: preparation, characterization and application as drug carrier. *J Biomed Nanotechnol*. 2009; 5(5):591-595. doi:10.1166/jbn.2009.1067

92. Cortes H, Hernandez-Parra H, Bernal-Chavez SA, et al. Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses. *Materials (Basel)*. 2021;14(12):3197. Published 2021 Jun 10. doi:10.3390/ma14123197
93. Hassan CM, Trakampan P, Peppas NA. Water Solubility Characteristics of Poly (vinyl alcohol) and Gels Prepared by Freezing/Thawing Processes. In: Amjad, Z. (eds) (2002) *Water Soluble Polymers*. Springer, Boston, MA. https://doi.org/10.1007/0-306-46915-4_3
94. Allaudin PMS, Kunchithapatham J. A review on preformulation studies of drugs. *International Journal of Pharmaceutical Research and development* 2012; 4 (05): 64-74.
95. Gupta KR, Pounikar AR, Umekar MJ. Drug Excipient Compatibility Testing Protocols and Characterization: A Review. *Asian Journal of Chemical Sciences*, (2019)6(3), 1–22. <https://doi.org/10.9734/ajocs/2019/v6i319000>.
96. Bao QY, Liu AY, Ma Y, et al. The effect of oil-water partition coefficient on the distribution and cellular uptake of liposome-encapsulated gold nanoparticles. *Colloids Surf B Biointerfaces*. 2016; 146:475-481. doi:10.1016/j.colsurfb.2016.06.046
97. Samy M, Abd El-Alim SH, Rabia AEG, Amin A, Ayoub MMH. Formulation, characterization and in vitro release study of 5-fluorouracil loaded chitosan nanoparticles. *Int J Biol Macromol*. 2020; 156:783-791. doi:10.1016/j.ijbiomac.2020.04.112.
98. Bhawana, Basniwal, R. K., Buttar, H. S., Jain, V. K., & Jain, N.. Curcumin nanoparticles: preparation, characterization, and antimicrobial study. *Journal of agricultural and food chemistry*. 2011; 59(5), 2056–2061. <https://doi.org/10.1021/jf104402t>

99. Zhang LL, Ma FF, Kuang YF, Cheng S, Long YF, Xiao QG. Highly sensitive detection of bovine serum albumin based on the aggregation of triangular silver nanoplates. *Spectrochim Acta A Mol Biomol Spectrosc.* 2016;154:98-102. doi:10.1016/j.saa.2015.10.019
- Loquercio A, Castell-Perez E, Gomes C, Moreira RG. Preparation of Chitosan-Alginate Nanoparticles for Trans-cinnamaldehyde Entrapment. *J Food Sci.* 2015;80(10):N2305-N2315. doi:10.1111/1750-3841.12997.
100. Xie F, Cheng Z, Cheng H, Yu P. Simultaneous determination of bendamustine and its active metabolite, gamma-hydroxy-bendamustine in human plasma and urine using HPLC-fluorescence detector: application to a pharmacokinetic study in Chinese cancer patients. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2014;960:98-104. doi:10.1016/j.jchromb.2014.04.027
101. Calvo NL, Maggio RM, Kaufman TS. A dynamic thermal ATR-FTIR/chemometric approach to the analysis of polymorphic interconversions. Cimetidine as a model drug. *J Pharm Biomed Anal.* 2014;92:90-97. doi:10.1016/j.jpba.2013.12.036
102. Chadha R, Bhandari S. Drug-excipient compatibility screening--role of thermoanalytical and spectroscopic techniques. *J Pharm Biomed Anal.* 2014;87:82-97. doi:10.1016/j.jpba.2013.06.016
103. Bharate SS, Kumar V, Vishwakarma RA. Determining Partition Coefficient (Log P), Distribution Coefficient (Log D) and Ionization Constant (pKa) in Early Drug Discovery. *Comb Chem High Throughput Screen.* 2016;19(6):461-469. doi:10.2174/1386207319666160502123917
104. Tiwari S, Kumar V, Randhawa S, Verma SK. Preparation and characterization of extracellular vesicles. *Am J Reprod Immunol.* 2021;85(2):e13367. doi:10.1111/aji.13367

105. Matalqah SM, Aiedeh K, Mhaidat NM, Alzoubi KH, Bustanji Y, Hamad I. Chitosan Nanoparticles as a Novel Drug Delivery System: A Review Article. *Curr Drug Targets*. 2020;21(15):1613-1624. doi:10.2174/1389450121666200711172536
106. Cohen-Sela E, Chorny M, Koroukhov N, Danenberg HD, Golomb G. A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles. *J Control Release*. 2009;133(2):90-95. doi:10.1016/j.jconrel.2008.09.073
107. Abdelwahed W, Degobert G, Stainmesse S, Fessi H. Freeze-drying of nanoparticles: formulation, process and storage considerations. *Adv Drug Deliv Rev*. 2006;58(15):1688-1713. doi:10.1016/j.addr.2006.09.017
108. Soliman NM, Shakeel F, Haq N, et al. Development and Optimization of Ciprofloxacin HCl-Loaded Chitosan Nanoparticles Using Box-Behnken Experimental Design. *Molecules*. 2022;27(14):4468. Published 2022 Jul 13. doi:10.3390/molecules27144468
109. Amin MK, Boateng JS. Comparison and process optimization of PLGA, chitosan and silica nanoparticles for potential oral vaccine delivery. *Ther Deliv*. 2019; 10(8):493-514. doi:10.4155/tde-2019-0038
110. Suzuki M, Takebe G, Takagi T, Tsukada H. Characterization of Novel Paclitaxel Nanoparticles Prepared by Laser Irradiation. *Chem Pharm Bull (Tokyo)*. 2022;70(4):269-276. doi:10.1248/cpb.c21-00994
111. Sharma AN, Upadhyay PK, Dewangan HK. Development, evaluation, pharmacokinetic and biodistribution estimation of resveratrol-loaded solid lipid nanoparticles for prostate cancer targeting. *J Microencapsul*. 2022; 39(6):563-574. doi:10.1080/02652048.2022.2135785

- 112.Hashad RA, Ishak RA, Fahmy S, Mansour S, Geneidi AS. Chitosan-tripolyphosphate nanoparticles: Optimization of formulation parameters for improving process yield at a novel pH using artificial neural networks. *Int J Biol Macromol.* 2016;86:50-58. doi:10.1016/j.ijbiomac.2016.01.042
- 113.Sharma H, Kumar K, Choudhary C, Mishra PK, Vaidya B. Development and characterization of metal oxide nanoparticles for the delivery of anticancer drug. *Artif Cells Nanomed Biotechnol.* 2016; 44(2):672-679. doi:10.3109/21691401.2014.978980
- 114.Malatesta M. Transmission Electron Microscopy as a Powerful Tool to Investigate the Interaction of Nanoparticles with Subcellular Structures. *Int J Mol Sci.* 2021;22(23):12789. Published 2021 Nov 26. doi:10.3390/ijms222312789
- 115.Wei X, Patil Y, Ohana P, et al. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Prometil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy. *Mol Pharm.* 2017;14(12):4339-4345. doi:10.1021/acs.molpharmaceut.6b00865
- 116.Forien JB, Uzuhashi J, Ohkubo T, et al. X-ray diffraction and in situ pressurization of dentine apatite reveals nanocrystal modulus stiffening upon carbonate removal. *Acta Biomater.* 2021; 120:91-103. doi:10.1016/j.actbio.2020.09.004
- 117.Eshrati Yeganeh F, Eshrati Yeganeh A, Fatemizadeh M, Farasati Far B, Quazi S, Safdar M. In vitro cytotoxicity and anti-cancer drug release behavior of methionine-coated magnetite nanoparticles as carriers. *Med Oncol.* 2022;39(12):252. Published 2022 Oct 12. doi:10.1007/s12032-022-01838-1

118. Stiepel RT, Pena ES, Ehrenzeller SA, et al. A predictive mechanistic model of drug release from surface eroding polymeric nanoparticles. *J Control Release*. 2022;351:883-895. doi:10.1016/j.jconrel.2022.09.067
119. Dupeyrón D, Kawakami M, Rieumont J, Carvalho JC. Formulation and Characterization of Anthocyanins-Loaded Nanoparticles. *Curr Drug Deliv*. 2017;14(1):54-64. doi:10.2174/1567201813666160915102151
120. Al-Nakashli R, Raveendran R, Khine YY, et al. Drug-Loading Content Influences Cellular Uptake of Polymer-Coated Nanocellulose. *Mol Pharm*. 2023;20(4):2017-2028. doi:10.1021/acs.molpharmaceut.2c00997
121. Khan RU, Khan M, Sohail A, et al. Efficacy of pentamidine-loaded chitosan nanoparticles as a novel drug delivery system for *Leishmania tropica*. *Trop Biomed*. 2022;39(4):511-517. doi:10.47665/tb.39.4.003
122. Jain AK, Thareja S. In vitro and in vivo characterization of pharmaceutical nanocarriers used for drug delivery. *Artif Cells Nanomed Biotechnol*. 2019;47(1):524-539. doi:10.1080/21691401.2018.1561457
123. Samy M, Abd El-Alim SH, Rabia AEG, Amin A, Ayoub MMH. Formulation, characterization and in vitro release study of 5-fluorouracil loaded chitosan nanoparticles. *Int J Biol Macromol*. 2020;156:783-791. doi:10.1016/j.ijbiomac.2020.04.112
124. Poy D, Akbarzadeh A, Ebrahimi Shahmabadi H, et al. Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study. *Chem Biol Drug Des*. 2016;88(4):568-573. doi:10.1111/cbdd.12786

125. Kumar P, Nagarajan A, Uchil PD. Analysis of Cell Viability by the MTT Assay. *Cold Spring Harb Protoc.* 2018;2018(6):10.1101/pdb.prot095505. Published 2018 Jun 1. doi:10.1101/pdb.prot095505
126. Bag A, Ghorai PK. Development of Quantum Chemical Method to Calculate Half Maximal Inhibitory Concentration (IC50). *Mol Inform.* 2016; 35(5):199-206. doi:10.1002/minf.201501004
127. Mi XJ, Park HR, Dhandapani S, Lee S, Kim YJ. Biologically synthesis of gold nanoparticles using *Cirsium japonicum* var. *maackii* extract and the study of anti-cancer properties on AGS gastric cancer cells. *Int J Biol Sci.* 2022; 18(15):5809-5826. Published 2022 Sep 21. doi:10.7150/ijbs.77734

List of Publications:

1. Pandey P, Dwivedi J, Shukla SS. Preparation, Optimization and Characterization of Bendamustine Loaded PLGA Nanoparticle. *Bio Gecko*; 2023, 12(3):2828-45. DOI : <http://biogecko.co.nz/.2023.v12.i03.pp2828-2845> .
2. Pandey P, Dwivedi J, Shukla SS. Targeted Approaches through Nanocarriers In Leukemia: A Review. *African Journal of Biological Sciences*; 2024, 6(2):1525-1532. doi: 10.33472/AFJBS.6.Si2.2024.1525-1532.

List of Poster Presented in Conferences

1. Poster Presented In International Conference On “Drug Discovery, Design And Delivery Approaches” Organised By Guru Nanak College Of Pharmaceutical Sciences, Dehradun, Uttrakhand, Dated 26/11/2022.
2. Poster Presented In International Conference On “Antimicrobial Resistance And Gut Microbiome: Rationalizing Prescriptions In Clinical Practice” Organised By Metro College Of Health Sciences & Research, Greater Noida, Uttar Pradesh, Dated 03-04 March 2023.